Edwards Lifesciences Corp. (EW) Thursday guided for 2020 sales of $4.5 billion to $5 billion.
The maker of devices for heart disease and critical care monitoring forecast 2020 adjusted per-share earnings of $6.05 to $6.30.
The company projects fiscal 2019 sales around the top of a range of $4 billion to $4.3 billion and adjusted per-share earnings of $5.50 to $5.65.
“In 2020, we are projecting another year of double-digit top-line and bottom-line growth while we continue to aggressively pursue breakthrough therapies for millions of patients suffering from structural heart diseases,” Chief Executive Michael Mussallem said.
The company projected global transcatheter valve therapy opportunities reaching more than $10 billion by 2024.
Edwards said its 2020 research and development is planned at 17% to 18% of sales.
